Ditchcarbon
  • Contact
  1. Organizations
  2. Baxalta Incorporated
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 3 months ago

Baxalta Incorporated Sustainability Profile

Company website

Baxalta Incorporated, a leading biopharmaceutical company, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 2015, Baxalta emerged from a spin-off of Baxter International, focusing on innovative therapies for rare diseases and complex conditions. The company is renowned for its specialised products in haemophilia, immunology, and oncology, with offerings such as Adynovate, a unique recombinant factor VIII therapy that enhances patient outcomes. Baxalta has established a strong market position, recognised for its commitment to research and development, which has led to significant advancements in treatment options. With a dedication to improving patient lives, Baxalta continues to be a key player in the biopharmaceutical industry, striving for excellence in every aspect of its operations.

DitchCarbon Score

How does Baxalta Incorporated's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

70

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Baxalta Incorporated's score of 70 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.

82%

Let us know if this data was useful to you

Baxalta Incorporated's reported carbon emissions

Inherited from Takeda Pharmaceutical Company Limited

Baxalta Incorporated, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which influences its climate commitments and initiatives. Baxalta's climate strategy is aligned with the broader goals set by its parent company, Takeda. This includes commitments to science-based targets (SBTi) and other sustainability initiatives. However, specific reduction targets or achievements for Baxalta itself have not been disclosed. As part of its corporate family relationship, emissions data and climate initiatives are cascaded from Takeda Pharmaceutical Company Limited, which operates at a cascade level of 3. This means that while Baxalta may not have its own distinct emissions data, it adheres to the sustainability framework established by Takeda, which is focused on reducing its overall carbon footprint and enhancing environmental stewardship. In summary, while Baxalta Incorporated does not provide specific emissions data or reduction targets, it is committed to the climate initiatives set forth by its parent company, Takeda Pharmaceutical Company Limited, reflecting a collective effort towards sustainability in the pharmaceutical industry.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20112012201320142015201620202021202220232024
Scope 1
-
-
-
-
00,000,000
00,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
-
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
000,000,000
000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

How Carbon Intensive is Baxalta Incorporated's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Baxalta Incorporated's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Baxalta Incorporated's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Baxalta Incorporated is in US, which has a low grid carbon intensity relative to other regions.

Baxalta Incorporated's Scope 3 Categories Breakdown

Baxalta Incorporated's Scope 3 emissions, which decreased by 29% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 63% of Scope 3 emissions.

Top Scope 3 Categories

2024
Purchased Goods and Services
63%
Capital Goods
8%
Upstream Transportation & Distribution
8%
End-of-Life Treatment of Sold Products
7%
Fuel and Energy Related Activities
5%
Business Travel
4%
Investments
2%
Employee Commuting
2%
Waste Generated in Operations
<1%
Processing of Sold Products
<1%

Baxalta Incorporated's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Baxalta Incorporated has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Baxalta Incorporated's Emissions with Industry Peers

CSL Behring N.V.

BE
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Glaxosmithkline

GB
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

AstraZeneca AB

SE
•
Pharmaceutical Preparation Manufacturing
Updated 3 months ago

Swedish Orphan Biovitrum

SE
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Celgene Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Let us know if this data was useful to you

Usage Policy

You're welcome to quote or reference data from this page, but please include a visible link back to this URL.

Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.

See our License Agreement for more details.

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251209.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
Use CaseSBTi-aligned baselining & progress trackingSupplier EngagementClimate-informed sourcing strategyEmission ReportingSustainable Finance
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelogWhitepaper
AboutTeamCareersLicense AgreementPrivacy